ECOG-ACRIN Cancer Research Group

ECOG-ACRIN Cancer Research Group Biomarker-driven research involving adults who have or are at risk of developing cancer

Do you have newly diagnosed multiple myeloma and are either ineligible for or willing to delay stem cell transplantation...
04/30/2026

Do you have newly diagnosed multiple myeloma and are either ineligible for or willing to delay stem cell transplantation? If so, you may be eligible to participate in clinical trial EAA181/EQUATE. More info here: https://bit.ly/eaa181equate

Michael Lidsky, MD of is leading EA2222/PUMP, a randomized phase 3 study for patients with colorectal liver metastases....
04/30/2026

Michael Lidsky, MD of is leading EA2222/PUMP, a randomized phase 3 study for patients with colorectal liver metastases. Learn more: https://bit.ly/ea2222-pump

EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan versus standard chemotherapy in patients with ...
04/30/2026

EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan versus standard chemotherapy in patients with advanced urothelial cancer. The trial aims to improve treatment options & guide further research. ➡️ https://bit.ly/ea8231-study

Help potentially improve the future of head and neck cancer treatment. Take part in clinical study EA3191 for patients w...
04/30/2026

Help potentially improve the future of head and neck cancer treatment. Take part in clinical study EA3191 for patients with squamous cell carcinoma of the head and neck (HNSCC) that has come back. Learn more: https://bit.ly/ea3191-study

Early onset is rising. Genetics explain only part of it. NPR explores how the may be a missing piece—highlighting th...
04/30/2026

Early onset is rising. Genetics explain only part of it. NPR explores how the may be a missing piece—highlighting the necessity of initiatives like our Microbiome Working Group:

Unlike many cancers, colorectal cancer has become more lethal for people at younger ages. Doctors are sleuthing out why.

Dr. Seth Pollack of Lurie Cancer Center is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combina...
04/29/2026

Dr. Seth Pollack of Lurie Cancer Center is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced DDLPS, UPS, & related poorly differentiated . More here: https://bit.ly/EA7222

The usual treatment for with early-stage includes two surgeries. The EA6244 study asks: could one surgery + close mo...
04/29/2026

The usual treatment for with early-stage includes two surgeries. The EA6244 study asks: could one surgery + close monitoring be just as effective for some people? More info: https://bit.ly/ea6244-study

In the Study, researchers are testing if genetically-matched drug combinations will be more effective than single drug...
04/29/2026

In the Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with . Learn more: http://bit.ly/ComboMATCH

Attending our Spring 2026 Group Meeting next week? Don't miss the Comis Symposium (5/5 @ noon), focused on 'Susceptibili...
04/28/2026

Attending our Spring 2026 Group Meeting next week? Don't miss the Comis Symposium (5/5 @ noon), focused on 'Susceptibility and Inflammation,' or the General Session (5/6 @ 9 am), ft. cutting-edge cancer vaccine development strategies. Read more:

A preview of the upcoming Spring Group Meeting, a recap of AACR 2026, and a call for respectful disagreement

Patients with aggressive B-cell lymphoma that has recurred or is resistant to treatment may be eligible to participate i...
04/28/2026

Patients with aggressive B-cell lymphoma that has recurred or is resistant to treatment may be eligible to participate in clinical trial EA4231. Learn more here: https://bit.ly/EA4231

Urothelial cancer is the most common type of bladder cancer. The EA8192 study is evaluating durvalumab and chemotherapy ...
04/28/2026

Urothelial cancer is the most common type of bladder cancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://bit.ly/ea8192-trialhttps://bit.ly/ea8192-trial

EA5221/ACHIEVE, led by Dr. Megan Baumgart, aims to help older patients with live longer while also maintaining a goo...
04/28/2026

EA5221/ACHIEVE, led by Dr. Megan Baumgart, aims to help older patients with live longer while also maintaining a good quality of life. Learn more: https://bit.ly/ea5221-achieve

Address

Philadelphia, PA

Telephone

+12157893631

Website

http://linktr.ee/ecog_acrin

Alerts

Be the first to know and let us send you an email when ECOG-ACRIN Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Our Story

We design and conduct cancer clinical trials, which are available to patients at nearly 1,200 member cancer centers and community hospitals in the US and internationally. We focus our research on adults who have or are at risk of developing cancer. The group is dedicated to achieving advances in all aspects of cancer care across all types of cancer. Our goal is to reduce the burden of cancer and improve the quality of life and survival in patients. Our primary source of funding is the National Cancer Institute, part of the National Institutes of Health.